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ABSTRACT 
Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a pruritic condition of 
pregnancy, characterized by an underlying elevation in circulating bile acids and liver derangement, 
and associated with adverse fetal outcomes, such as preterm labor and stillbirth. Limited 
understanding of the underlying pathophysiology and mechanisms involved in adverse outcomes 
has previously restricted treatment options and pregnancy management.  Recent advances in these 
research fields provide tantalizing targets to improve the care of pregnant women affected by this 
condition.  
 
Introduction 
Intrahepatic cholestasis of pregnancy (ICP), also called obstetric cholestasis, is a liver condition of 
pregnancy, characterized by pruritus and the biochemical finding of elevated serum bile acids, often 
in the presence of other signs of liver dysfunction. By definition, ICP is confined to pregnancy and the 
peripartum period and is diagnosed following exclusion of other etiologies for cholestasis. In 
addition to the maternal symptomatology, ICP can be associated with adverse fetal outcomes, such 
as spontaneous preterm birth, meconium staining of the amniotic fluid, and stillbirth;1 hence, 
appropriate recognition and management are significiant.  
 
The incidence of ICP varies dependent upon geographic location and ethnicity. For example, the 
incidence is 4% in Chile;2 in the United Kingdom, it is 0.7%, but is higher in women of Indian or 
Pakistani origin,3 while the incidence in China has recently been estimated at 1.2%, based on more 
than 100,000 hospital births.4 Within the Californian population, genetic ancestry mapping has 
demonstrated higher levels of ICP in women of Native American ethnicity.5 
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ICP is more common in women with pre-existing hepatitis C and gallstone disease; hence, the 
benefit of serum screening and liver ultrasound in all women diagnosed with the condition.6 Its 
incidence is also higher in women with multiple gestation pregnancies7 and in those who conceived 
using assisted reproduction.8 
 
Symptoms 
The hallmark symptom of ICP is pruritus, i.e. “itching in the absence of a rash”; yet, scratching can 
often lead to secondary skin changes. Traditionally, pruritus is described on the palms and soles, but 
ICP-associated pruritus can be generalized.9 Itching ranges from mild to a debilitating and intense 
symptom, and it is typically worse at night. Excoriated lesions (Figure) can become complicated by 
secondary infection. The onset of pruritus often precedes biochemical derangement.10 making the 
diagnosis one to be considered in any woman with the characteristic itch in pregnancy. 
Further symptoms relate to the effects of liver impairment. Bilirubin is elevated in approximately 
10% of cases, and in this group jaundice can be detected ( the condition was initially recognized as 
recurrent jaundice in pregnancy), and symptoms  suggestive of malabsorption of fats, e.g. 
steatorrhea, can occur.11 If there is evidence of malabsorption, impaired coagulation can occur, 
secondary to reduced vitamin K absorption, although this is not common, and a recent study into the 
coagulation parameters of 319 women with ICP did not demonstrate any women with abnormal 
coagulation parameters.12 
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Pruritus in Pregnancy and ICP  
The cause of pruritus in ICP is not fully understood, although a number of possible pruritogens have 
been identified. It has long been established that bile acids can elicit itch, when applied to the skin,13 
and the lowering of serum bile acids with the use of ursodeoxycholic acid (UDCA) treatment for ICP 
is mirrored by a reduction in itch intensity.14 There is some experimental evidence for a role of bile 
acids in pruritus as the secondary bile acid deoxycholic acid (DCA) has been shown to activate the G-
protein coupled receptor, TGR5, on cutaneous afferent neurons, thereby eliciting a scratch response. 
The concentrations of DCA used for these experiments were much higher than are observed in 
women with ICP.15 Also, the clinical relevance of this observation is not clear, as the pattern of bile 
acid levels and subjective itch intensity do not correlate well in ICP,10 so bile acids alone are unlikely 
to cause pruritus in the disorder. 
 
Lysophosphatidic acid (LPA) is a potent pruritogen16 that is produced from lysophosphatidyl choline 
by the action of the enzyme autotaxin. Autotaxin activity is elevated in the serum of patients with 
pruritic cholestatic conditions,17 and it is higher in women with ICP than with other liver-associated 
disorders of pregnancy.18   Genetic variants of the enzyme adiponutrin (PNPLA3) have been found in 
women with ICP; this enzyme is expressed in the liver and skin, and catalyses the breakdown of 
LPA.19   
 
Progesterone, which rises during pregnancy, is destined for excretion in part by conjugation with a 
sulfate group, which renders the hormone more soluble. Sulfated metabolites of progesterone are 
elevated in ICP compared with normal pregnancy,20 and of these, 5-pregnan-3-20-diol-sulfate 
(PM3S) is directly associated with the level of pruritus experienced by the patient.21 PM3S has been  
demonstrated to signal via TGR5 in a cell line, when exposed to PM3S at the physiologic 
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concentrations found in the serum of women with ICP.  It has triggered a scratch response, when 
administered to mice intradermally.21 LPA and PM3S are  the likely candidates to be the pruritogens 
in ICP.  
 
Etiology 
Maternal disease 
The etiology of ICP is influenced by a combination of genetic, endocrine ,and environmental factors. 
Evidence for a genetic etiology includes an increased risk in first degree relatives,22 the presence of 
mutations in biliary transporters, e.g. the Bile Salt Export Pump (BSEP/ABCB11) and Multi-Drug 
Resistance protein 3 (MDR3/ABCB4),23, 24 and polymorphisms that confer susceptibility in these 
genes and the principal nuclear receptor that influences bile acid homeostasis, Farnesoid X Receptor 
(FXR).25 By definition, women with ICP are not typically cholestatic outside of pregnancy. As such, it 
has been proposed that the  onset in pregnancy could relate to epigenetic changes. In support of 
this, altered DNA methylation in the promoter regions of FXR and another nuclear receptor, 
pregnane X receptor (PXR), has been demonstrated in women with ICP, compared to normal 
pregnancies, although the functional relevance of this has not yet been determined.26 
Another potential explanation for the onset of ICP in pregnancy is the altered gestational endocrine 
environment. Onset is most common in the third trimester, when circulating estrogen and 
progesterone are reaching their peak, and thus it is unsurprising that elevated serum concentrations 
of metabolites of both hormones have been associated with ICP. Indeed, some women with a 
history of ICP develop pruritus on consumption of the combined oral contraceptive pill.27 Signalling 
via the estrogen receptor ERα, 17β-estradiol  can impair the induction of BSEP expression by bile 
acid-liganded FXR in a mouse model28 and human cell line.29 In addition to their association with 
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pruritus, sulfated progesterone metabolites can impair bile acid influx into30 and efflux from31 the 
hepatocyte, and partially antagonise FXR,32 all of which can exacerbate cholestasis. 
Environmental factors have been proposed for influencing the etiology of ICP. Epidemiologic studies 
have shown an increased prevalence of the disorder in the winter months,33 with low maternal 
vitamin D levels or reduced dietary selenium intake being proposed as plausible contributors. 
Selenium intake from food varies throughout the yea,r and there is reduced sun exposure in the 
winter. ICP also occurs more commonly in patients with reactive hepatitis C serology.34 
 
Fetal disease 
Several recent studies have evaluated the relationship between adverse pregnancy outcome and 
biochemical derangements in women with ICP. The two largest prospective cohort studies, and 
several smaller series, have demonstrated that elevated maternal serum bile acid concentrations 
(i.e. ≥40 µmol/L) are associated with increased rates of spontaneous and iatrogenic preterm labor, 
meconium-stained amniotic fluid, fetal hypoxia and, in the largest study, stillbirth.1, 35-38 This 
observation suggests that bile acids may also be elevated in the fetal/placental circulation and that 
this results in complications, but the specific mechanisms have not been fully elucidated. The 
stillbirths suffered by women with ICP are unpredictable and occur in normally grown fetuses 
without evidence of chronic placental insufficiency.39 In view of this, a number of theories exist as to 
a sudden catastrophic cause of the stillbirth. Abnormal placental vascular responses have been 
suggested as a possible cause, with sudden vasospasm potentially responsible for fetal death; in 
support of this the bile acid taurocholate, which is markedly elevated in ICP, impaired placental 
arterial vascular pressure elevation in an ex vivo model.40 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Ovadia and Williamson 
7 
 
Bile acids have also been found to impair fetal cardiomyocyte function in vitro,41 and thus a sudden 
cardiac arrhythmia has been suggested as a possible cause of the intrauterine death. Fetal 
echocardiography demonstrated significantly different findings with regard to velocities at the mitral 
and tricuspid valves in fetuses of women with “severe” ICP (total bile acids >40 µmol/l) compared 
with women with lower bile acid levels or normal pregnancies,42 and differences were seen in 
myocardial performance indices43 and myocardial deformation,44 although the clinical implications of 
these findings have yet to be elucidated. 
 
IBile acids may affect neonatal respiratory function, as elevated bile acids have been found in the 
bronchioalveolar lavage fluid from neonates born from pregnancies complicated by ICP, which was 
not observed in those born from control pregnancies.45 This may affect the outcome of babies born 
to such pregnancies, as bile acids reduce lung surfactant in a rat model of cholestatic pregnancy, by 
acting on macrophages via TGR5 to induce the action of phospholipase A2 which degrades 
surfactant.46 In another rat model they were found to affect respiratory parameters by signalling via 
FXR at the hypoglossal nerve.47 
 
Management 
The drugs for which placebo-controlled studies have been performed in the treatment of ICP are 
summarized in Table. Ursodeoxycholic acid (UDCA) has the most experimental data to support its 
use. It is a hydrophilic bile acid that improves bile acid profiles in cholestatic liver disorders via 
multiple mechanisms, including enhanced biliary excretion (reviewed by Lazaridis48). It also reduces 
the extent of the elevation of fetal bile acids in ICP.49 UDCA is the most widely prescribed 
pharmacologic treatment for ICP, although the most recent Cochrane review (2013) was still not 
able to recommend its use for ICP for fetal benefit based on existing evidence.50  Subsequently, a 
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number of further trials have been undertaken, and the most recent meta-analyses of these 
demonstrated that UDCA improves biochemical parameters and pruritus intensity.51, 52 Whilst the 
large PITCH study showed benefit in itch scoring on a Visual Analogue Scale, it was by a smaller 
degree than that predetermined as necessary for worthwhile symptomatic benefit by patients and 
practitioners.14 The impact of UDCA treatment on fetal and neonatal outcomes has not been 
evaluated with an adequately powered study, although the Phase II PITCHES clinical trial 
commencing this year in the UK will aim to address this. A meta-analysis of all trials that compared 
UDCA to another treatment demonstrated that its use reduces the likelihood of adverse pregnancy 
outcomes, but this study was limited by relatively small numbers of direct comparisons of UDCA with 
placebo.51 Interestingly, UDCA was shown to improve the fetal bile acid profile in umbilical cord 
blood, with up-regulation of placental expression of the export pump ATP-binding cassette (ABC)G2 
providing a potential explanation for enhancement of fetal bile acid excretion across the placenta.53 
Additionally, UDCA was able to reverse the arrhythmogenic effect of taurocholic acid in an in vitro 
rat model of the fetal heart.54 
 
S-adenosyl-L-methionine (SAMe) is required for phospholipid biosynthesis, hence is thought to be 
hepatoprotective in ICP. Small studies in ICP have demonstrated conflicting results, therefore there 
is not reliable evidence upon which to recommend clinical benefit. Additionally, the requirement for 
daily intravenous infusion precludes practical and patient-acceptable administration for many 
women with ICP. Activated charcoal, guar gum,and cholestyramine have been tried, based on their 
ability to prevent of intestinal bile acid resorption; a single study with activated charcoal showed a 
tantalising improvement in biochemistry, but the small size of this trial has not justified its clinical 
use. Results for cholestyramine and guar gum have been fairly equivocal, with no evidence that they 
out-perform UDCA, and concern regarding impairment of fat-soluble vitamin intake associated with 
cholestyramine preclude its routine use in pregnancy. Dexamethasone has been used, as it inhibits 
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adrenal production of estrogen precursors, thus lowering placental estrogen production. Results of a 
single study were not significant and concerns regarding recurrent glucocorticoid use in pregnancy 
(i.e. risks of maternal impaired glucose tolerance and childhood behavioral effects) have deterred 
many clinicians from its use. 
 
Rifampicin has been used in combination with UDCA for women with severe and resistant disease to 
monotherapy with UDCA alone. Rifampicin is a PXR agonist, thus works via a different and 
synergistic mechanism to reduce serum bile acids. It is successful in reducing total serum bile acids 
and pruritus in around 50% of women with ICP.55 Interestingly, rifampicin has been shown to reduce 
autotaxin expression in cell lines, which could explain its mechanism in improving pruritus.17 
 
Aqueous cream with 1 or 2% menthol diminishes th pruritus in some women, and vitamin K 
treatment may reduce the risk of peripartum haemorrhage in women with steatorrhoea, who are at 
risk of vitamin K malabsorption. 
 
Women with ICP are often admitted to the hospital for regular fetal surveillance, for example with 
fetal movement chart completion, cardiotocography, biophysical profiling, ultrasound of growth 
parameters,and Doppler flow velocimetry; yet, evidence for the value of these tests has not been 
established. Even where differences in recorded values are obtained from the normal population 
(e.g. umbilical artery Doppler measures),56 using these to predict fetuses at risk of adverse outcomes 
has been elusive. 
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Delivery is often expedited in women with ICP due to concerns about the risk of adverse pregnancy 
outcomes, although international consensus as to the optimal gestation week for deliver has not 
been reached. Typically, the balance of risk versus implications of preterm delivery has resulted in 
labour being induced around 37-38 gestational weeks. Interestingly, two recent studies using 
different experimental approaches have suggested that delivery around 36 weeks’ gestation may be 
associated with the best outcomes. Using a Californian cohort of pregnant women and 
fetal/neonatal mortality data, the risk of death was found to be lower with delivery at 36 weeks than 
expectant management for women with ICP (perinatal mortality 4.7 vs. 19.2 per 10,000).57 In the 
second study, morbidity in addition to mortality were considered in terms of quality adjusted life 
years (QALYs) with a decision-analysis model, which also found that delivery at 36 weeks would give 
the best outcomes.58  How this affects clinical decisions remains to be determined, given increasing 
evidence of the negative effects of delivery at earlier gestations on intellectual development59 (even 
at 37-40 weeks’ gestation).  Evidence regarding induction of labor for women with ICP does not 
indicate any increased risk of emergency caesarean section or fetal asphyxia (determined by Apgar 
score <7 at 5 minutes).60 
 
Associated Conditions 
Bile acids have traditionally been viewed as detergent molecules that aid digestion of fats, secondary 
to their hydrophobic properties; owever, they have important roles in metabolism, with multiple 
signalling effects on downstream organs, such as the pancreas and adipose tissue.  The two major 
bile acid receptors currently recognized are the nuclear receptor FXR and the G-protein coupled cell 
surface receptor TGR5. Bile acids binding of these receptors results in multiple downstream 
metabolic effects on glucose and lipid metabolism. In view of the elevated bile acids found in ICP, it 
is  unsurprising that it is not simply a condition limited to liver impairment and adverse fetal 
outcomes. A number of studies, using different methodologies and patient demographics, have 
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demonstrated that women with ICP are at a greater risk of developing gestational diabetes mellitus 
(GDM),61, 62 dyslipidemia, and proportionately larger babies than women with uncomplicated 
pregnancies.63 Mouse models have also demonstrated that the girls of cholestatic pregnancies also 
develop impaired glucose tolerance when challenged with a Western diet,64 and the 16-year-old 
children of ICP pregnancies had dyslipidemia, higher BMI and waist / hip girth measurements 
compared with the children of uncomplicated pregnancies.  Six-month-old offspring of cholestatic 
rat pregnancies demonstrated altered hypothalamic neuropeptide Y and proopiomelanocortin 
levels, suggesting a mechanism for appetite stimulation in the offspring of cholestatic pregnancies.65 
 
ICP has been associated with the subsequent onset of pre-eclampsia in a retrospective study that 
compared 78 women with ICP to 300 healthy pregnant women.66 For women entered into the 
Swedish Medical Birth Register between 1997 and 2009, women with ICP had an adjusted odds ratio 
2.62 (95% CI 2.32-2.78) of also having pre-eclampsia in pregnancy.62 The mechanism for this 
association has not been determined.  
 
Long-term Implications 
Women with ICP have slightly higher long term risks of cancer of the liver and biliary tree (HR 3.61; 
95% CI 1.68-7.77, and 2.62; 95% CI 1.26-5.46, respectively),67 as well as higher rates of other 
hepatobiliary diseases, most commonly cholelithiasis.6 In addition, a Swedish population-based 
study using national disease databases also found mildly elevated rates of diabetes mellitus, thyroid 
disease, psoriasis, inflammatory polyarthropathies, Crohn’s disease, and cardiovascular disease.67 
Women with ICP were found to have altered P-wave characteristics on electrocardiography 
compared with women with normal pregnancies,68 and women with severe ICP had significantly 
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altered QT intervals on ECG compared to those with mild disease or normal pregnancies,69 perhaps 
reflecting this long-term cardiovascular risk. 
 
Future Directions 
As further insights are gained into the etiology of ICP, improvements in the management of patients 
affected by the condition become possible. Understanding the underlying pathophysiology will 
certainly enable us to: 
 Develop predictive biomarkers enabling targeted obstetric care to women at risk of 
developing ICP from early pregnancy on. Putative biomarkers, such as autotaxin18 and the 
sulphated progesterone metabolites,21 have been suggested and are promising for future 
larger-scale studies. 
 Improve diagnostic testing to determine which women symptomatic of pruritus in 
pregnancy have ICP, and which are suffering from benign gestational pruritus (estimated to 
occur in 25% of pregnancies).9 Identifying alternative diagnostic markers to total serum bile 
acids will also alleviate the confusion caused by the postprandial elevation seen in bile acids, 
differing diagnostic methodology (enzymatic, liquid chromatography mass spectrometry) 
and interlaboratory reference ranges. 
 Determine which ICP pregnancies are associated with adverse fetal outcomes – currently, 
the term “severe” ICP is used for women with bile acids >40 µmol/L. Several studies have 
demonstrated associations between elevations in serum bile acid or earlier disease onset 
and adverse outcome;1, 35-38 however, it is currently impossible to predict which of these 
more “at risk” pregnancies will have adverse outcomes. 
 Prevent disease onset - both in terms of prevention of cholestasis, perhaps by enhancing bile 
acid excretion from the hepatocyte and impairing its gastrointestinal reuptake, or by 
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reducing endogenous bile acid production, as well prevention of the consequences of 
cholestasis, such as protection of the hepatocyte from the toxic build-up of bile acids, 
prevention of pruritogen production, avoidance of development of metabolic disturbances 
such as dyslipidemia and GDM, and reduction of bile acid transplacental transfer to the 
fetus. 
 Manage the condition - in terms of improvements in circulating bile acid profile, targeting 
the cause of pruritus (pruritogens or pathways), reducing adverse pregnancy outcomes and 
optimising timing of delivery. The development of pharmacological treatments targeting the 
bile acid receptors FXR and TGR5 provide novel agents with therapeutic potential for ICP. 
Giving drugs with potential widespread metabolic implications to pregnant women should 
be undertaken with great caution.  
 Identify and address long-term health implications – by understanding how ICP is linked to 
future health problems for mothers and offspring to whom specific therapeutic 
interventions can be targeted. 
Research to elucidate the etiology of ICP is likely to uncover metabolic factors of relevance to other 
diseases, which is an enticing prospect given the increasing pandemic of diabetes, obesity, and 
related diseases. 
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Table. Summary of evidence for pharmacologic treatments used in ICP. 
Drug Numbers in 
treatment 
group 
Improved biochemistry with drug Improved pruritus with drug Improved fetal outcome with drug Reference 
UDCA 8 Total bile acids, ALT, bilirubin 
significant p<0.001 
Significant p<0.001 Later delivery significant p<0.05 Diaferia, 1996
70
 
8 Bilirubin, AST, ALT significant p<0.05 Significant p<0.02 Later delivery significant p<0.01 Palma, 1997
71
 
47 ALT, bilirubin significant p<0.01 
In subgroup with bile acids ≥40µmol/L  
(n=12), significant reduction in ALT and 
total bile acids 
Not significant 
In subgroup with bile acids 
≥40µmol/L  (n=12), significant 
reduction in pruritus 
Not significant; 12/47 preterm birth Glantz, 2005
72
 
34 Total bile acids, ALT significant 
p<0.05 
Significant p<0.05  Preterm delivery, intrapartum fetal 
distress, MSAF and neonatal 
asphyxia all p<0.05 
Liu, 2006
73
 
56 ALT, GGT, bilirubin significant p<0.01 Not significant p=0.11 
In women with raised serum bile 
acids there was a significant 
reduction in pruritus 
MSAF significant p<0.05 Chappell, 2012
14
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9 Not significant Significant p<0.05 Not significant Joutsiniemi 
2014
74
 
SAMe 6 Bilirubin, ALT, total bile acids 
significant p<0.05 
“High dose” significant p<0.01 Not reported Frezza, 1984
75
 
15 Significant p<0.01 Significant, p value not given Not significant Frezza, 1990
76
 
9 Not significant Not significant Not significant Ribalta, 1991
77 
Activated 
charcoal 
10 Significant p<0.05 No difference No difference Kaaja, 1994
78
 
Guar gum 19 Statistical comparison with placebo 
not presented 
Patient-assessed, but not 
investigator-assessed, pruritus 
significant p<0.05 
No effect detailed Riikonen, 2000
79
 
Cholestyramine 42 9/42  - AST, ALT,  8/42 – total bile 
acids improved; UDCA significantly 
better p<0.02 
8/42 reduction in pruritus score 
by 50%. UDCA significantly better 
p<0.001 
5/42 preterm birth, lower Apgar 
score than UDCA group p<0.05 
Kondrackiene, 
2005
80
* 
Compared with 
UDCA 
Dexamethasone 36 Not significant Not significant Not significant Glantz, 2005
72
 
Rifampicin 27 14/27 (54%) improved bile acids 10/15 reported improved 
pruritus 
25/27 had adverse neonatal 
outcomes (mainly prematurity 
Geenes, 2015
55
* 
Observational 
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23/27)  study 
UDCA, ursodeoxycholic acid; ALT, alanine transaminase; AST, aspartate transaminase; MSAF, meconium-stained amniotic fluid; GGT, gamma-glutamyl 
transferase; SAMe, S-adenosyl-L-methionine. 
Results are shown from publications in the English language available by PubMed searching, comparing drug with placebo, unless otherwise indicated 
where no placebo-controlled study has yet been performed.  
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Figure legend 
Figure. Excoriated skin lesions in patients with ICP. (A) mild, early skin changes, and (B) appearance 
of skin lesions following prolonged scratching (Fig. 1A donated by Dr. George Kroumpouzos, and Fig. 
1B is used with permission of Jenny Chambers, ICP Support, Sutton Coldfield, England).  
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